Gelteq Limited (GELS) Cash Flow Statement

NASDAQ: GELSOperating cash, capex, free cash flow and buybacks.

Where GELS’s cash came from and went, FY2025

June 30, 2025 · Australian dollars
Cash from operations
−A$5.5M
Capital expenditures
A$642,234
387.7% of revenue
Free cash flow
−A$6.2M
−3,721.1% margin
Returned to shareholders
—
Change in cash
A$320,126
cash at year-end A$344,648
Acquisitions & other: A$642,234Acquisitions & otherA$642,234Borrowing: A$482,770BorrowingA$482,770Shares issued: A$7.9MShares issuedA$7.9MCurrency & other: A$125,071Currency & otherA$125,071Cash used in operations: A$5.5MCash used in operationsA$5.5M · 60%Other financing: A$1.9MOther financingA$1.9M · 21%Investments (net): A$736,839Investments (net)A$736,839 · 8%Capital expenditures: A$642,234Capital expendituresA$642,234 · 7%Added to cash: A$320,126Added to cashA$320,126 · 3%A$9.2M
Cash from operations
−A$5.5M
Capital expenditures
−A$642,234
Investments (net)
−A$736,839
Acquisitions & other
+A$642,234
Net borrowing (repayment)
+A$482,770
Shares issued
+A$7.9M
Other financing
−A$1.9M
Currency & other
+A$125,071
Change in cash
A$320,126

Drawn to scale: where the cash came from and how it was used. Hover for values.

GELS operating cash flow, capex and free cash flow

Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)

GELS cash flow trends, FY2023–FY2025

Gelteq Limited cash flow trends
MetricTrendThenLatestChange
Operating cash flow−A$1.8MFY2023−A$5.5MFY2025—
Capital expendituresA$75,931FY2023A$642,234FY2025+190.8%/yr
Free cash flow−A$1.8MFY2023−A$6.2MFY2025—
Free cash flow margin−2,312.5%FY2023−3,721.1%FY2025−1,408.6 pts
Capex / revenue95.1%FY2023387.7%FY2025+292.6 pts

Change is the average annual growth (CAGR) or the difference between the first and latest year.

GELS cash flow by activity

OperatingInvestingFinancingChange in cash

GELS net income vs operating cash flow

Net incomeOperating cash flow

Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).

GELS cash flow statement in Australian dollars

Gelteq Limited annual cash flow statement
FY2025FY2024FY2023
Operating activities
Net income−A$6.6M−A$3.5M−A$3.5M
Depreciation & amortizationA$1.3MA$1.2MA$1.2M
Other non-cash items−A$149,024A$1.3MA$528,180
Cash from operating activities−A$5.5M−A$1.1M−A$1.8M
Investing activities
Capital expenditures−A$642,234−A$148,170−A$75,931
Investments (net)−A$736,839−A$148,170−A$75,931
Acquisitions & other investingA$642,234A$148,170A$75,931
Cash from investing activities−A$736,839−A$148,170−A$75,931
Financing activities
Net borrowing (repayment)A$482,770A$843,939A$721,229
Shares issuedA$7.9MA$0A$1.4M
Other financing−A$1.9MA$0−A$121,844
Cash from financing activitiesA$6.5MA$843,939A$2.0M
Summary
Net change in cashA$320,126−A$374,702A$236,739
Cash at end of periodA$344,648A$24,522A$399,224
Free cash flow−A$6.2M−A$1.2M−A$1.8M
Free cash flow margin−3,721.1%—−2,312.5%
Capex / revenue387.7%—95.1%

Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in Australian dollars as reported; data from EODHD.

GELS cash generation

In fiscal 2025 (ended June 30, 2025), Gelteq generated -A$5.5 million of cash from operations and spent A$0.6 million on capital expenditures, leaving free cash flow of -A$6.2 million, −3,721.1% of revenue. Cash and equivalents rose by A$0.3 million over the year.

Related: GELS income statement, GELS balance sheet. See the GELS stock overview for the latest quote and news.

GELS cash flow FAQ

What is Gelteq's free cash flow?

Gelteq's free cash flow was -A$6.2 million in fiscal 2025: -A$5.5 million of operating cash flow minus A$0.6 million of capital expenditures It was -A$1.2 million a year earlier..

How much cash does Gelteq generate from operations?

Gelteq generated -A$5.5 million of cash from operating activities in fiscal 2025.

How much does Gelteq spend on capital expenditures?

Gelteq spent A$0.6 million on capital expenditures in fiscal 2025, 387.7% of revenue, compared with A$0.1 million the year before.

Drug Manufacturers - Specialty & Generic: cash flow